BCRX—They are also developing a HCV nucleoside analog sans the prodrug strategy which I doubt should be taken seriously.
Do you mean they are developing a nucleoside as opposed to a nucleotide—i.e. they are developing something that looks like the first illustration in #msg-42396728? If so, that is indeed a discredited approach.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”